These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22673640)

  • 1. Leveraging kinase inhibitors to develop small molecule tools for imaging kinases by fluorescence microscopy.
    Zhang Z; Kwiatkowski N; Zeng H; Lim SM; Gray NS; Zhang W; Yang PL
    Mol Biosyst; 2012 Oct; 8(10):2523-6. PubMed ID: 22673640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioorthogonal probes for polo-like kinase 1 imaging and quantification.
    Budin G; Yang KS; Reiner T; Weissleder R
    Angew Chem Int Ed Engl; 2011 Sep; 50(40):9378-81. PubMed ID: 21948435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells.
    Raab M; Pachl F; Krämer A; Kurunci-Csacsko E; Dötsch C; Knecht R; Becker S; Kuster B; Strebhardt K
    Cell Res; 2014 Sep; 24(9):1141-5. PubMed ID: 24980956
    [No Abstract]   [Full Text] [Related]  

  • 4. Small-molecule inhibitors for targeting polo-like kinase 1.
    Kolosenko I; Palm-Apergi C
    Future Med Chem; 2020 Aug; 12(16):1457-1460. PubMed ID: 32638616
    [No Abstract]   [Full Text] [Related]  

  • 5. PLK1-Targeted Fluorescent Tumor Imaging with High Signal-to-Background Ratio.
    Hou JT; Ko KP; Shi H; Ren WX; Verwilst P; Koo S; Lee JY; Chi SG; Kim JS
    ACS Sens; 2017 Oct; 2(10):1512-1516. PubMed ID: 28920432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1.
    Pearson RJ; Blake DG; Mezna M; Fischer PM; Westwood NJ; McInnes C
    Cell Chem Biol; 2018 Sep; 25(9):1107-1116.e4. PubMed ID: 30017915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polo-like kinases inhibitors.
    Garuti L; Roberti M; Bottegoni G
    Curr Med Chem; 2012; 19(23):3937-48. PubMed ID: 22709006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
    Lv X; Yang X; Zhan MM; Cao P; Zheng S; Peng R; Han J; Xie Z; Tu Z; Liao C
    Eur J Med Chem; 2019 Dec; 184():111769. PubMed ID: 31629162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
    Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
    Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.
    Lénárt P; Petronczki M; Steegmaier M; Di Fiore B; Lipp JJ; Hoffmann M; Rettig WJ; Kraut N; Peters JM
    Curr Biol; 2007 Feb; 17(4):304-15. PubMed ID: 17291761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enabling and disabling polo-like kinase 1 inhibition through chemical genetics.
    Burkard ME; Santamaria A; Jallepalli PV
    ACS Chem Biol; 2012 Jun; 7(6):978-81. PubMed ID: 22422077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
    Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
    Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs by numbers: reaction-driven de novo design of potent and selective anticancer leads.
    Spänkuch B; Keppner S; Lange L; Rodrigues T; Zettl H; Koch CP; Reutlinger M; Hartenfeller M; Schneider P; Schneider G
    Angew Chem Int Ed Engl; 2013 Apr; 52(17):4676-81. PubMed ID: 23166089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
    Steegmaier M; Hoffmann M; Baum A; Lénárt P; Petronczki M; Krssák M; Gürtler U; Garin-Chesa P; Lieb S; Quant J; Grauert M; Adolf GR; Kraut N; Peters JM; Rettig WJ
    Curr Biol; 2007 Feb; 17(4):316-22. PubMed ID: 17291758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
    Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing polo-like kinase 1 inhibitors.
    Huang X; Xie Z; Liao C
    Future Med Chem; 2020 May; 12(10):869-871. PubMed ID: 32233804
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1.
    Keppner S; Proschak E; Schneider G; Spänkuch B
    ChemMedChem; 2009 Nov; 4(11):1806-9. PubMed ID: 19746360
    [No Abstract]   [Full Text] [Related]  

  • 19. Drugging Plk1: An attractive approach to inhibit androgen receptor signaling.
    Strebhardt K
    Cell Cycle; 2015; 14(14):2193-4. PubMed ID: 26030710
    [No Abstract]   [Full Text] [Related]  

  • 20. Splice Modulation Synergizes Cell Cycle Inhibition.
    Trieger KA; La Clair JJ; Burkart MD
    ACS Chem Biol; 2020 Mar; 15(3):669-674. PubMed ID: 32004428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.